Key result
Beta blockers show uncertain benefit in HFpEF due to limited available evidence.
Why the study?
While beta blockers unequivocally reduce mortality in HFrEF, their beneficial effects in patients with HFpEF are not well established.
This review highlights the lack of established evidence supporting the routine use of beta blockers in patients with HFpEF without alternative indications.
Lacks support for routine beta-blocker use in HFpEF without other indications; leaves open whether dedicated RCTs would demonstrate benefit.
Beta blockers are a recommended therapy in patients with heart failure with reduced ejection fraction(HFrEF). Beta blockers markedly and unequivocally reduce mortality in patients with heart failure with reduced ejection fraction. However, the beneficial effects of beta blockers in patients with heart failure with preserved ejection fraction(HFpEF) are not well established. In this review, we will assess the evidence basis of the recommendations for beta blockers and discuss emerging concerns about the use of beta blockers in patients with HFpEF. The available evidence for beta blockers is limited and it remains uncertain whether beta blockers have a beneficial role in the treatment of HFpEF in the absence of an alternative indication for their use.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2019) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Beta blockers was evaluated. The available evidence for beta blockers is limited and it remains uncertain whether they have a beneficial role in the treatment of heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: